Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Physiol Rep ; 12(13): e16129, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38955668

ABSTRACT

Cardiotrophin-1 (CT-1), a member of the interleukin (IL)-6 cytokine family, has renoprotective effects in mouse models of acute kidney disease and tubulointerstitial fibrosis, but its role in glomerular disease is unknown. To address this, we used the mouse model of nephrotoxic nephritis to test the hypothesis that CT-1 also has a protective role in immune-mediated glomerular disease. Using immunohistochemistry and analysis of single-cell RNA-sequencing data of isolated glomeruli, we demonstrate that CT-1 is expressed in the glomerulus in male mice, predominantly in parietal epithelial cells and is downregulated in mice with nephrotoxic nephritis. Furthermore, analysis of data from patients revealed that human glomerular disease is also associated with reduced glomerular CT-1 transcript levels. In male mice with nephrotoxic nephritis and established proteinuria, administration of CT-1 resulted in reduced albuminuria, prevented podocyte loss, and sustained plasma creatinine, compared with mice administered saline. CT-1 treatment also reduced fibrosis in the kidney cortex, peri-glomerular macrophage accumulation and the kidney levels of the pro-inflammatory mediator complement component 5a. In conclusion, CT-1 intervention therapy delays the progression of glomerular disease in mice by preserving kidney function and inhibiting renal inflammation and fibrosis.


Subject(s)
Cytokines , Kidney Glomerulus , Mice, Inbred C57BL , Animals , Male , Cytokines/metabolism , Cytokines/genetics , Mice , Kidney Glomerulus/metabolism , Kidney Glomerulus/pathology , Disease Models, Animal , Humans , Fibrosis , Glomerulonephritis/metabolism , Glomerulonephritis/pathology , Glomerulonephritis/drug therapy
2.
Int J Mol Sci ; 24(9)2023 Apr 22.
Article in English | MEDLINE | ID: mdl-37175390

ABSTRACT

Diseases affecting the glomerulus, the filtration unit of the kidney, are a major cause of chronic kidney disease. Glomerular disease is characterised by injury of glomerular cells and is often accompanied by an inflammatory response that drives disease progression. New strategies are needed to slow the progression to end-stage kidney disease, which requires dialysis or transplantation. Thymosin ß4 (Tß4), an endogenous peptide that sequesters G-actin, has shown potent anti-inflammatory function in experimental models of heart, kidney, liver, lung, and eye injury. In this review, we discuss the role of endogenous and exogenous Tß4 in glomerular disease progression and the current understanding of the underlying mechanisms.


Subject(s)
Renal Insufficiency, Chronic , Thymosin , Humans , Disease Progression , Kidney Glomerulus , Renal Dialysis
3.
Sci Rep ; 12(1): 12172, 2022 07 16.
Article in English | MEDLINE | ID: mdl-35842494

ABSTRACT

Plasma ultrafiltration in the kidney occurs across glomerular capillaries, which are surrounded by epithelial cells called podocytes. Podocytes have a unique shape maintained by a complex cytoskeleton, which becomes disrupted in glomerular disease resulting in defective filtration and albuminuria. Lack of endogenous thymosin ß4 (TB4), an actin sequestering peptide, exacerbates glomerular injury and disrupts the organisation of the podocyte actin cytoskeleton, however, the potential of exogenous TB4 therapy to improve podocyte injury is unknown. Here, we have used Adriamycin (ADR), a toxin which injures podocytes and damages the glomerular filtration barrier leading to albuminuria in mice. Through interrogating single-cell RNA-sequencing data of isolated glomeruli we demonstrate that ADR injury results in reduced levels of podocyte TB4. Administration of an adeno-associated viral vector encoding TB4 increased the circulating level of TB4 and prevented ADR-induced podocyte loss and albuminuria. ADR injury was associated with disorganisation of the podocyte actin cytoskeleton in vitro, which was ameliorated by treatment with exogenous TB4. Collectively, we propose that systemic gene therapy with TB4 prevents podocyte injury and maintains glomerular filtration via protection of the podocyte cytoskeleton thus presenting a novel treatment strategy for glomerular disease.


Subject(s)
Kidney Diseases , Podocytes , Albuminuria , Animals , Cells, Cultured , Doxorubicin , Genetic Therapy , Kidney Glomerulus , Mice , Thymosin
4.
Methods Mol Biol ; 2067: 53-59, 2020.
Article in English | MEDLINE | ID: mdl-31701445

ABSTRACT

Diabetic nephropathy is associated with injury and loss of podocytes, specialized epithelial cells that are critical for glomerular filtration. This chapter describes a method of isolating and culturing podocyte cells from mouse adult kidneys. In this way, podocytes with genetic modifications can be obtained from transgenic animals and they can be used to study the effects of the diabetic environment in vitro.


Subject(s)
Diabetic Nephropathies/pathology , Podocytes/pathology , Primary Cell Culture/methods , Animals , Cells, Cultured , Diabetic Nephropathies/genetics , Disease Models, Animal , Humans , Immunomagnetic Separation , Mice , Mice, Transgenic , Signal Transduction
5.
J Pathol ; 246(4): 485-496, 2018 12.
Article in English | MEDLINE | ID: mdl-30125361

ABSTRACT

Planar cell polarity (PCP) pathways control the orientation and alignment of epithelial cells within tissues. Van Gogh-like 2 (Vangl2) is a key PCP protein that is required for the normal differentiation of kidney glomeruli and tubules. Vangl2 has also been implicated in modifying the course of acquired glomerular disease, and here, we further explored how Vangl2 impacts on glomerular pathobiology in this context. Targeted genetic deletion of Vangl2 in mouse glomerular epithelial podocytes enhanced the severity of not only irreversible accelerated nephrotoxic nephritis but also lipopolysaccharide-induced reversible glomerular damage. In each proteinuric model, genetic deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9, an enzyme involved in tissue remodelling. In addition, by interrogating microarray data from two cohorts of renal patients, we report increased VANGL2 transcript levels in the glomeruli of individuals with focal segmental glomerulosclerosis, suggesting that the molecule may also be involved in certain human glomerular diseases. These observations support the conclusion that Vangl2 modulates glomerular injury, at least in part by acting as a brake on MMP9, a potentially harmful endogenous enzyme. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.


Subject(s)
Cell Polarity , Glomerulosclerosis, Focal Segmental/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Kidney Glomerulus/metabolism , Membrane Proteins/metabolism , Nephrosis, Lipoid/metabolism , Nerve Tissue Proteins/metabolism , Podocytes/metabolism , Adult , Animals , Case-Control Studies , Cells, Cultured , Disease Models, Animal , Enzyme Activation , Female , Glomerulosclerosis, Focal Segmental/genetics , Glomerulosclerosis, Focal Segmental/pathology , Glomerulosclerosis, Focal Segmental/physiopathology , Humans , Intracellular Signaling Peptides and Proteins/genetics , Kidney Glomerulus/pathology , Kidney Glomerulus/physiopathology , Male , Matrix Metalloproteinase 9/metabolism , Membrane Proteins/genetics , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Nephrosis, Lipoid/genetics , Nephrosis, Lipoid/pathology , Nephrosis, Lipoid/physiopathology , Nerve Tissue Proteins/deficiency , Nerve Tissue Proteins/genetics , Podocytes/pathology , Signal Transduction , Young Adult
6.
Expert Opin Biol Ther ; 18(sup1): 185-192, 2018 07.
Article in English | MEDLINE | ID: mdl-29727205

ABSTRACT

INTRODUCTION: There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-ß4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-ß4 could be a novel therapeutic direction for CKD. AREAS COVERED: Here, we review the current evidence on the actions of thymosin-ß4 in the kidney in health and disease. Using transgenic mice, two recent studies have demonstrated that endogenous thymosin-ß4 is dispensable for healthy kidneys. In contrast, lack of endogenous thymosin-ß4 exacerbates mouse models of glomerular disease and angiotensin-II-induced renal injury. Administration of exogenous thymosin-ß4, or its metabolite, Ac-SDKP, has shown therapeutic benefits in a range of experimental models of kidney disease. EXPERT OPINION: The studies conducted so far reveal a protective role for thymosin-ß4 in the kidney and have shown promising results for the therapeutic potential of exogenous thymosin-ß4 in CKD. Further studies should explore the mechanisms by which thymosin-ß4 modulates kidney function in different types of CKD. Ac-SDKP treatment has beneficial effects in many experimental models of kidney disease, thus supporting its potential use as a new treatment strategy.


Subject(s)
Renal Insufficiency, Chronic/drug therapy , Thymosin/physiology , Thymosin/therapeutic use , Animals , Disease Models, Animal , Fibrosis/pathology , Fibrosis/prevention & control , Humans , Inflammation/drug therapy , Inflammation/pathology , Kidney/drug effects , Kidney/pathology , Mice , Mice, Transgenic , Renal Insufficiency, Chronic/pathology
7.
Kidney Int ; 90(5): 1056-1070, 2016 11.
Article in English | MEDLINE | ID: mdl-27575556

ABSTRACT

Glomerular disease is characterized by morphologic changes in podocyte cells accompanied by inflammation and fibrosis. Thymosin ß4 regulates cell morphology, inflammation, and fibrosis in several organs and administration of exogenous thymosin ß4 improves animal models of unilateral ureteral obstruction and diabetic nephropathy. However, the role of endogenous thymosin ß4 in the kidney is unknown. We demonstrate that thymosin ß4 is expressed prominently in podocytes of developing and adult mouse glomeruli. Global loss of thymosin ß4 did not affect healthy glomeruli, but accelerated the severity of immune-mediated nephrotoxic nephritis with worse renal function, periglomerular inflammation, and fibrosis. Lack of thymosin ß4 in nephrotoxic nephritis led to the redistribution of podocytes from the glomerular tuft toward the Bowman capsule suggesting a role for thymosin ß4 in the migration of these cells. Thymosin ß4 knockdown in cultured podocytes also increased migration in a wound-healing assay, accompanied by F-actin rearrangement and increased RhoA activity. We propose that endogenous thymosin ß4 is a modifier of glomerular injury, likely having a protective role acting as a brake to slow disease progression.


Subject(s)
Glomerulonephritis/metabolism , Podocytes/metabolism , Thymosin/metabolism , Animals , Cell Movement , Cells, Cultured , Cytoskeleton/metabolism , Fibrosis , Glomerulonephritis/pathology , Kidney Glomerulus/pathology , Macrophages , Male , Mice, Inbred C57BL , Mice, Knockout
8.
Expert Opin Biol Ther ; 15 Suppl 1: S187-90, 2015.
Article in English | MEDLINE | ID: mdl-26096077

ABSTRACT

Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-ß4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-ß4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-ß4 may also have therapeutic benefit in CKD.


Subject(s)
Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/genetics , Thymosin/physiology , Thymosin/therapeutic use , Adult , Animals , Fibrosis/drug therapy , Fibrosis/genetics , Humans , Inflammation/drug therapy , Inflammation/genetics , Kidney/drug effects , Kidney/pathology , Mice , Rats , Wound Healing/drug effects , Wound Healing/genetics
9.
PLoS One ; 8(6): e65402, 2013.
Article in English | MEDLINE | ID: mdl-23776477

ABSTRACT

Monocarboxylate transporter 8 (MCT8) is a well-established thyroid hormone (TH) transporter. In humans, MCT8 mutations result in changes in circulating TH concentrations and X-linked severe global neurodevelopmental delay. MCT8 is expressed in the human placenta throughout gestation, with increased expression in trophoblast cells from growth-restricted pregnancies. We postulate that MCT8 plays an important role in placental development and transplacental TH transport. We investigated the effect of altering MCT8 expression in human trophoblast in vitro and in a Mct8 knockout mouse model. Silencing of endogenous MCT8 reduced T3 uptake into human extravillous trophoblast-like cells (SGHPL-4; 40%, P<0.05) and primary cytotrophoblast (15%, P<0.05). MCT8 over-expression transiently increased T3 uptake (SGHPL-4∶30%, P<0.05; cytotrophoblast: 15%, P<0.05). Silencing MCT8 did not significantly affect SGHPL-4 invasion, but with MCT8 over-expression T3 treatment promoted invasion compared with no T3 (3.3-fold; P<0.05). Furthermore, MCT8 silencing increased cytotrophoblast viability (∼20%, P<0.05) and MCT8 over-expression reduced cytotrophoblast viability independently of T3 (∼20%, P<0.05). In vivo, Mct8 knockout reduced fetal:placental weight ratios compared with wild-type controls at gestational day 18 (25%, P<0.05) but absolute fetal and placental weights were not significantly different. The volume fraction of the labyrinthine zone of the placenta, which facilitates maternal-fetal exchange, was reduced in Mct8 knockout placentae (10%, P<0.05). However, there was no effect on mouse placental cell proliferation in vivo. We conclude that MCT8 makes a significant contribution to T3 uptake into human trophoblast cells and has a role in modulating human trophoblast cell invasion and viability. In mice, Mct8 knockout has subtle effects upon fetoplacental growth and does not significantly affect placental cell viability probably due to compensatory mechanisms in vivo.


Subject(s)
Membrane Transport Proteins/genetics , Monocarboxylic Acid Transporters/metabolism , Placenta/metabolism , Placentation , Thyroid Hormones/metabolism , Analysis of Variance , Animals , Apoptosis/physiology , Cell Movement/physiology , Cell Proliferation , Cells, Cultured , England , Female , Humans , Mice , Mice, Knockout , Organ Size , Placenta/cytology , Pregnancy , RNA, Small Interfering/genetics , Symporters , Trophoblasts/metabolism
10.
Nat Clin Pract Endocrinol Metab ; 5(1): 45-54, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19079273

ABSTRACT

The transplacental passage of thyroid hormones from the maternal circulation to the fetal circulation within the human hemochorial placenta is important for normal fetal development, particularly the development of the central nervous system. The role of maternal thyroid hormones is particularly important in the first half of pregnancy, before the onset of endogenous thyroid hormone production in the fetus. The human placenta regulates the quantity and composition of different forms of transported thyroid hormones to ensure that the requisite levels are present in the fetus for each stage of development. Transplacental thyroid hormone supply to the fetus is modulated by several factors, including the following proteins: plasma membrane transporters, which regulate the passage of thyroid hormones in and out of cells; iodothyronine deiodinases, which metabolize thyroid hormones; and proteins within trophoblast cells, which bind thyroid hormones. In pathological situations of either maternal or fetal thyroid hormone deficiency during pregnancy, the placenta seems to lack the full compensatory mechanisms necessary to optimize maternal-fetal transfer of thyroid hormones. Inadequate passage of thyroid hormones can lead to suboptimal fetal thyroid hormone levels, which might contribute to the neurodevelopmental delay associated with such conditions. Thus, maintaining normal maternal thyroid hormone status is likely to be the primary factor in ensuring adequate transplacental thyroid hormone passage and appropriate iodide supply to the fetus.


Subject(s)
Fetus/metabolism , Maternal-Fetal Exchange/physiology , Placenta/metabolism , Placenta/physiology , Thyroid Hormones/metabolism , Female , Humans , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...